CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Bargaining power of buyers
3.2.4.Bargaining power of suppliers
3.2.5.Thereat of new entrants
3.2.6.Threat of substitutes
3.2.7.Intensity of competitive rivalry
3.3.Top player positioning, 2020
3.1.Regulation
3.2.Market dynamics
3.2.1.Drivers
3.2.1.1.Rise in incidences and prevalence of various cancer types
3.2.1.2.Increase in demand for safe and non-invasive procedures
3.2.1.3.Advantages of liquid biopsy launches and technology
3.2.2.Restraints
3.2.2.1.Lack of awareness in developing and underdeveloped regions
3.2.3.Opportunities
3.2.3.1.Use of liquid biopsy for treatment of rare cancer
3.2.3.2.Untapped potential of emerging markets
3.3.Impact Analysis
3.4.Impact Analysis of the Covid-19 on Liquid Biopsy Market
CHAPTER 4:LIQUID BIOPSY MARKET, BY PRODUCT & SERVICES
4.1.Overview
4.1.1.Market size and forecast
4.2.Kits & Reagents
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market share analysis, by country
4.3.Platforms & Instruments
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market share analysis, by country
4.4.Services
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market share analysis, by country
CHAPTER 5:LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER
5.1.Overview
5.1.1.Market size and forecast
5.2.Circulating Tumor Cell
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Circulating Tumor DNA
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Extracellular Vesicles
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Other Biomarkers
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
CHAPTER 6:LIQUID BIOPSY MARKET, BY CANCER TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Lung Cancer
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Breast Cancer
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.5.Colorectal Cancer
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
6.6.Prostate cancer
6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country
6.7.Liver cancer
6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country
6.8.Other Cancers
6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country
CHAPTER 7:LIQUID BIOPSY MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospital and Laboratory
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.Government and Academic Research Centers
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
CHAPTER 8:LIQUID BIOPSY MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America Liquid Biopsy Market, by Product & Service
8.2.3.North America Liquid Biopsy Market, by Circulating Biomarker
8.2.4.North America Liquid Biopsy Market, by Cancer Type
8.2.5.North America Liquid Biopsy Market, by End User
8.2.6.Market size and forecast, by country
8.2.7.U.S.
8.2.7.1.U.S. Liquid biopsy market, by Product & Service
8.2.7.2.U.S. Liquid biopsy market, by Circulating Biomarker
8.2.7.3.U.S. Liquid biopsy market, by Cancer Type
8.2.7.4.U.S. Liquid biopsy market, by End User
8.2.8.Canada
8.2.8.1.Canada Liquid biopsy market, by Product & Service
8.2.8.2.Canada Liquid biopsy market, by Circulating Biomarker
8.2.8.3.Canada Liquid biopsy market, by Cancer Type
8.2.8.4.Canada Liquid biopsy market, by End User
8.2.9.Mexico
8.2.9.1.Mexico Liquid biopsy market, by Product & Service
8.2.9.2.Mexico liquid biopsy market, by Circulating Biomarker
8.2.9.3.Mexico Liquid biopsy market, by Cancer Type
8.2.9.4.Mexico Liquid biopsy market, by End User
8.3.Europe
8.3.1.Key market trends, growth factors, and opportunities
8.3.3.Europe Market size and forecast, by Product & Service
8.3.4.Europe Market size and forecast, by Circulating Biomarker
8.3.5.Europe Market size and forecast, by Cancer Type
8.3.6.Europe Market size and forecast, by End User
8.3.7.Market size and forecast, by country
8.3.8.Germany
8.3.8.1.Germany Liquid biopsy market, by Product & Service
8.3.8.2.Germany Liquid Biopsy Market, by Circulating Biomarker
8.3.8.3.Germany Liquid Biopsy Market, by Cancer Type
8.3.8.4.Germany Liquid Biopsy Market, by End User
8.3.9.France
8.3.9.1.France Liquid biopsy market, by Product & Service
8.3.9.2.France Liquid Biopsy Market, by Circulating Biomarker
8.3.9.3.France Liquid Biopsy Market, by Cancer Type
8.3.9.4.France Liquid Biopsy Market, by End User
8.3.10.UK
8.3.10.1.UK Liquid biopsy market, by Product & Service
8.3.10.2.UK Liquid Biopsy Market, by Circulating Biomarker
8.3.10.3.UK Liquid Biopsy Market, by Cancer Type
8.3.10.4.UK Liquid Biopsy Market, by End User
8.3.11.Italy
8.3.11.1.Italy Liquid biopsy market, by Product & Service
8.3.11.2.Italy Liquid Biopsy Market, by Circulating Biomarker
8.3.11.3.Italy Liquid Biopsy Market, by Cancer Type
8.3.11.4.Italy Liquid Biopsy Market, by End User
8.3.12.Spain
8.3.12.1.Spain Liquid biopsy market, by Product & Service
8.3.12.2.Spain Liquid Biopsy Market, by Circulating Biomarker
8.3.12.3.Spain Liquid Biopsy Market, by Cancer Type
8.3.12.4.Spain Liquid Biopsy Market, by End User
8.3.13.Rest of Europe
8.3.13.1.Rest of Europe Liquid biopsy market, by Product & Service
8.3.13.2.Rest of Europe Liquid Biopsy Market, by Circulating Biomarker
8.3.13.3.Rest of Europe Liquid Biopsy Market, by Cancer Type
8.3.13.4.Rest of Europe Liquid Biopsy Market, by End User
8.4.Asia-Pacific
8.4.1.Key market trends and opportunities
8.4.2.Asia-Pacific Market size and forecast, by Product & Service
8.4.3.Asia-Pacific Market size and forecast, by Circulating Biomarker
8.4.4.Asia-Pacific Market size and forecast, by Cancer Type
8.4.5.Asia-Pacific Market size and forecast, by End User
8.4.6.Market size and forecast, by country
8.4.7.Japan
8.4.7.1.Japan Liquid Biopsy Market, by Product & Service
8.4.7.2.Japan Liquid Biopsy Market, by Circulating Biomarker
8.4.7.3.Japan Liquid Biopsy Market, by Cancer Type
8.4.7.4.Japan Liquid Biopsy Market, by End User
8.4.8.China
8.4.8.1.China Liquid Biopsy Market, by Product & Service
8.4.8.2.China Liquid Biopsy Market, by Circulating Biomarker
8.4.8.3.China Liquid Biopsy Market, by Cancer Type
8.4.8.4.China Liquid Biopsy Market, by End User
8.4.9.Australia
8.4.9.1.Australia Liquid Biopsy Market, by Product & Service
8.4.9.2.Australia Liquid Biopsy Market, by Circulating Biomarker
8.4.9.3.Australia Liquid Biopsy Market, by Cancer Type
8.4.9.4.Australia Liquid Biopsy Market, by End User
8.4.10.India
8.4.10.1.India Liquid Biopsy Market, by Product & Service
8.4.10.2.India Liquid Biopsy Market, by Circulating Biomarker
8.4.10.3.India Liquid Biopsy Market, by Cancer Type
8.4.10.4.India Liquid Biopsy Market, by End User
8.4.11.South Korea
8.4.11.1.South Korea Liquid Biopsy Market, by Product & Service
8.4.11.2.South Korea Liquid Biopsy Market, by Circulating Biomarker
8.4.11.3.South Korea Liquid Biopsy Market, by Cancer Type
8.4.11.4.South Korea Liquid Biopsy Market, by End User
8.4.12.Taiwan
8.4.12.1.Taiwan Liquid Biopsy Market, by Product & Service
8.4.12.2.Taiwan Liquid Biopsy Market, by Circulating Biomarker
8.4.12.3.Taiwan Liquid Biopsy Market, by Cancer Type
8.4.12.4.Taiwan Liquid Biopsy Market, by End User
8.4.13.Rest of Asia-Pacific
8.4.13.1.Rest of Asia-Pacific Liquid Biopsy Market, by Product & Service
8.4.13.2.Rest of Asia-Pacific Liquid Biopsy Market, by Circulating Biomarker
8.4.13.3.Rest of Asia-Pacific Liquid Biopsy Market, by Cancer Type
8.4.13.4.Rest of Asia-Pacific Liquid Biopsy Market, by End User
8.5.LAMEA
8.5.1.Key market trends, growth factors, and opportunities
8.5.3.LAMEA Market size and forecast, by Product & Service
8.5.4.LAMEA Market size and forecast, by Circulating Biomarker
8.5.5.LAMEA Market size and forecast, by Cancer Type
8.5.6.LAMEA Market size and forecast, by End User
8.5.7.Market size and forecast, by country
8.5.8.Brazil
8.5.8.1.Brazil Liquid Biopsy Market, by Product & Service
8.5.8.2.Brazil Liquid Biopsy Market, by Circulating Biomarker
8.5.8.3.Brazil Liquid Biopsy Market, by Cancer Type
8.5.8.4.Brazil Liquid Biopsy Market, by End User
8.5.9.Turkey
8.5.9.1.Turkey Liquid Biopsy Market, by Product & Service
8.5.9.2.Turkey Liquid Biopsy Market, by Circulating Biomarker
8.5.9.3.Turkey Liquid Biopsy Market, by Cancer Type
8.5.9.4.Turkey Liquid Biopsy Market, by End User
8.5.10.Saudi Arabia
8.5.10.1.Saudi Arabia Liquid Biopsy Market, by Product & Service
8.5.10.2.Saudi Arabia Liquid Biopsy Market, by Circulating Biomarker
8.5.10.3.Saudi Arabia Liquid Biopsy Market, by Cancer Type
8.5.10.4.Saudi Arabia Liquid Biopsy Market, by End User
8.5.11.South Africa
8.5.11.1.South Africa Liquid Biopsy Market, by Product & Service
8.5.11.2.South Africa Liquid Biopsy Market, by Circulating Biomarker
8.5.11.3.South Africa Liquid Biopsy Market, by Cancer Type
8.5.11.4.South Africa Liquid Biopsy Market, by End User
8.5.12.Rest of LAMEA
8.5.12.1.Rest of LAMEA Liquid Biopsy Market, by Product & Service
8.5.12.2.Rest of LAMEA Liquid Biopsy Market, by Circulating Biomarker
8.5.12.3.Rest of LAMEA Liquid Biopsy Market, by Cancer Type
8.5.12.4.Rest of LAMEA Liquid Biopsy Market, by End User
CHAPTER 9:COMPANY PROFILES
9.1.BIO-RAD LABORATORIES, INC.
9.1.1.1.Company overview
9.1.1.2.Company snapshot
9.1.1.3.Operating business segments
9.1.1.4.Product portfolio
9.1.1.5.Business performance
9.1.1.6.Key strategic moves and developments
9.2.BIOCEPT, INC.
9.2.1.1.Company overview
9.2.1.2.Company snapshot
9.2.1.3.Operating business segments
9.2.1.4.Product portfolio
9.2.1.5.Business performance
9.2.1.6.Key strategic moves and developments
9.3.GUARDANT HEALTH INC.
9.3.1.1.Company overview
9.3.1.2.Company snapshot
9.3.1.3.Operating business segments
9.3.1.4.Product portfolio
9.3.1.5.Business performance
9.3.1.6.Key strategic moves and developments
9.4.ILLUMINA, INC.
9.4.1.1.Company overview
9.4.1.2.Company snapshot
9.4.1.3.Operating business segments
9.4.1.4.Product portfolio
9.4.1.5.Business performance
9.4.1.6.Key strategic moves and developments
9.5.F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.)
9.5.1.1.Company overview
9.5.1.2.Company snapshot
9.5.1.3.Operating business segments
9.5.1.4.Product portfolio
9.5.1.5.Business performance
9.5.1.6.Key strategic moves and developments
9.6.JOHNSON & JOHNSON
9.6.1.1.Company overview
9.6.1.2.Company snapshot
9.6.1.3.Operating business segments
9.6.1.4.Product portfolio
9.6.1.5.Business performance
9.7.LABORATORY CORPORATION OF AMERICA HOLDINGS
9.7.1.1.Company overview
9.7.1.2.Company snapshot
9.7.1.3.Operating business segments
9.7.1.4.Product portfolio
9.7.1.5.Business performance
9.7.1.6.Key strategic moves and developments
9.8.MDXHEALTH SA
9.8.1.1.Company overview
9.8.1.2.Company snapshot
9.8.1.3.Operating business segments
9.8.1.4.Product portfolio
9.8.1.5.Business performance
9.8.1.6.Key strategic moves and developments
9.9.QIAGEN N.V.
9.9.1.1.Company overview
9.9.1.2.Company snapshot
9.9.1.3.Operating business segments
9.9.1.4.Product portfolio
9.9.1.5.Business performance
9.9.1.6.Key strategic moves and developments
9.10.THERMO FISHER SCIENTIFIC
9.10.1.1.Company overview
9.10.1.2.Company snapshot
9.10.1.3.Operating business segments
9.10.1.4.Product portfolio
9.10.1.5.Business performance
9.10.1.6.Key strategic moves and developments
